Starting November 11, South Korea will launch a free national COVID-19 vaccination campaign utilizing the newly introduced Moderna XFG variant-adapting vaccine, specifically targeting high-risk infants and children aged 6 months to 11 years who face severe vulnerability to viral complications.
Qualify High-Risk Children for Free Vaccines
- Targeted Access: Only high-risk pediatric populations—such as immunocompromised children and those residing in vulnerable care facilities—are eligible for this free vaccine rollout.
- Dosing Precision: The required number of injections ranges from one to two doses, strictly determined by the child’s prior vaccination history.
- Clinical Consultation: Parents must verify previous immunization records via official portals and consult medical staff prior to administration.
Emergency Vaccine Introduction Bridges a Critical Pediatric Gap
For years, children under the age of 12 lacked authorized domestic vaccine options tailored to their demographic, leaving high-risk families vulnerable during winter viral surges. To close this epidemiological gap, the Ministry of Food and Drug Safety expedited the emergency introduction of the Moderna XFG vaccine on October 28. While older cohorts including adults aged 65 and over initiated their seasonal immunization schedules in October, this new regulatory action ensures that high-risk pediatric patients receive synchronized protection.
The Korea Disease Control and Prevention Agency structured the campaign to run through April 30, 2027.
Eligibility for the Moderna XFG vaccine is governed by rigorous, age-stratified medical guidelines. For infants and toddlers aged 6 months to 4 years, qualifying conditions extend beyond primary immunodeficiencies to include chronic pulmonary, cardiac, hepatic, or renal diseases, as well as neuromuscular disorders. Conditions requiring intensive daily care, such as severe cerebral palsy or Down syndrome, also meet the threshold.
For children aged 5 and older, the framework requires documented diagnoses such as active oncologic treatment for blood cancers or solid tumors, ongoing immunosuppressive therapy following organ transplantation, or innate immune system deficiencies. Attending physicians possess the clinical discretion to authorize vaccination if a patient exhibits an equivalent immunocompromised state not explicitly listed in standard administrative tables.
| Vaccination Status | Ages 6 Months to 4 Years | Ages 5 Years to 11 Years |
|---|---|---|
| Unvaccinated | 2 doses of Moderna XFG (4–8 week interval) | 2 doses of Moderna XFG (4–8 week interval) |
| Prior Pfizer 1-dose | 2 doses of Moderna XFG | 1 dose of Moderna XFG (minimum 3–8 week interval) |
| Prior Pfizer 2-dose (incomplete) | 1 dose of Moderna XFG (minimum 8-week interval) | 1 dose of Moderna XFG (minimum 8-week interval) |
| Completed Primary Series | Annual booster (1 dose, or 2 for immunocompromised) | Annual booster (1 dose, or 2 for immunocompromised) |
Operational Logistics and Administration Protocols Across Designated Centers
Parents and legal guardians must complete specific administrative requirements before visiting designated inoculation sites. Official verification documents—including medical certificates, physician opinion letters, or facility admission confirmations—are recommended to substantiate high-risk status. However, public health authorities note that if the administering physician clinically determines the child meets immunocompromised criteria during the consultation, paper documentation can be waived.
Authorized medical facilities and contracted clinics can be located via the online Immunization Assistant portal. Following administration, clinical guidelines mandate a mandatory observation period of 20 to 30 minutes within the facility to monitor for acute hypersensitivity reactions or adverse events before safe discharge home.
Consult Medical Teams Before Child Vaccination
Because the required number of doses and intervals vary depending on prior vaccination history and vaccine type, parents should check their child's previous immunization records in advance and consult with the attending medical team before vaccination. After returning home, children should be given plenty of rest.
Protect Vulnerable Children Through Seasonal Rollout Participation
The pediatric rollout unfolds against the backdrop of broader seasonal vaccination efforts across the country. Korea Disease Control and Prevention Agency figures indicate that broader national programs have achieved steady engagement, with approximately 3.91 million individuals aged 65 and older participating in the current 2026–2027 seasonal campaign.
We ask that parents actively participate in vaccination so that children at high risk of severe illness can spend the winter safely,
KDCA Commissioner Lim Seung-kwan stated, emphasizing the urgency of protecting vulnerable populations as seasonal temperatures decline.
References
- Korea Disease Control and Prevention Agency (KDCA). Official Press Release on Pediatric COVID-19 National Immunization. November 2026.
- Ministry of Food and Drug Safety (MFDS). Emergency Introduction and Regulatory Approval of Moderna XFG Vaccine. October 2026.
- Immunization Assistant Portal. National Contracted Medical Institution Guidelines and Dosage Standards. 2026.
